astroflyery1 Posted - 12 minutes ago

$STRO I’m holding 22.000 Shares of this company and I couldn’t care less of this steep decline in share price today. I’m here for the long term. My confidence in Sutro Biopharma is very strong. They have top-talent working hard on next-generation cancer therapeutics. The pipeline is enormous. Management has a proven track record of monetizing its pipeline. The future is bright for this company. And I also admire their commitment to DEIB (Diversity, Equality, Inclusion & Belonging). There’s is significant data coming in 1H25. I will wait and enjoy the time until then.

astroflyery1 Posted - 21 minutes ago

$STRO By highlighting these candidates and discussing their strategy around exatecan ADCs, Sutro hopes to increase awareness and visibility of their earlier-stage assets, which could hold significant value in the future.

astroflyery1 Posted - 21 minutes ago

$STRO Sutro has planned a research forum this Fall where they aim to provide updates on their drug development progress. In particular, they want to "unpack" their progress on STRO-004 and provide more information on their future plans. This could offer more insights into their broader pipeline and help investors or stakeholders better understand the potential of their drug candidates.

astroflyery1 Posted - 22 minutes ago

$STRO Sutro is particularly focused on pursuing exatecan-based ADCs (antibody-drug conjugates). Exatecan is a potent topoisomerase I inhibitor, and coupling it with an antibody allows it to be delivered directly to cancer cells, potentially increasing efficacy while reducing toxicity. This class of drug conjugates holds promise in treating various cancers.

astroflyery1 Posted - 22 minutes ago

$STRO Sutro has several promising drug candidates in its pipeline, including STRO-004, STRO-005, STRO-006, and STRO-007. These drugs represent various potential therapies that target different cancer types or use different mechanisms of action.

astroflyery1 Posted - 23 minutes ago

$STRO Lung cancer represents a large therapeutic market, and Sutro sees this as a major revenue opportunity. Even if they can only treat 1-2% of the lung cancer patient population, they believe this would still be a significant commercial success. Sutro is preparing to enroll the first patient for a Phase 2 clinical trial targeting NSCLC later this year. This trial is part of their strategy to further validate their FRα-targeting approach in a larger population of lung cancer patients.

astroflyery1 Posted - 24 minutes ago

$STRO Pediatric AML Opportunity: Sutro's pivotal trial for pediatric AML is currently ongoing. They believe this opportunity is important because the patients in this trial are in dire need of better therapeutic options. Sutro is taking a global approach to this trial, aiming to enroll patients as quickly as possible. If successful, this trial could potentially result in the company obtaining a "priority review voucher" from the FDA. This voucher is a special incentive that allows companies to expedite the FDA review process for a future drug, which could help Sutro bring the AML treatment to market faster, particularly for pediatric relapsed or refractory (PROC) AML.

BBQQ Posted - 2 hours ago

$STRO so what’s deal here

Sillyspuh Posted - 8 hours ago

$STRO Why is this down today?

G101SPM Posted - 13 hours ago

$STRO $4.63 bid. DAC (2) $3.87. EXIT $9.50. UPDATE: Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 - 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose (RP2D) - - Luvelta in combination with bevacizumab demonstrate d encouraging preliminary antitumor activity (35% response rate) across all explored dose ranges - - Expansion at RP2D is ongoing with an additional 23 patients enrolled to date; expansion data are expected in the first half of 2025 - - No new safety signals were observed compared with either agent alone -

astroflyery1 Posted - 1 day ago

$STRO The data are promising, particularly the 56% ORR at the optimal dose and the fact that efficacy was observed regardless of FRα expression. However, small sample size and early-phase data mean it’s still too early to draw definitive conclusions about the long-term benefit or how this compares to existing therapies. If the results hold in larger, later-phase trials, Luvelta could be a valuable option for treating ovarian cancer.

DonCorleone77 Posted - 1 day ago

$STRO Sutro announces data from Phase 1b study of Luvelta in combo with Bevacizumab Sutro Biopharma announced updated data from the ongoing Phase 1b study of luveltamab tazevibulin in combination with bevacizumab for patients with epithelial ovarian cancer in a poster presentation at the 2024 European Society For Medical Oncology Congress in Barcelona, Spain. In this study, luvelta plus bevacizumab has demonstrated encouraging antitumor activity in patients with late-stage ovarian cancer irrespective of Folate Receptor-alpha expression, including patients with no FRalpha expression, and prior bevacizumab treatment, with an overall response rate of 35%. These early data in combination may offer a non-biomarker driven approach to treat patients with EOC. The expansion phase of the study is ongoing at the recommended phase 2 dose of luvelta in combination with bevacizumab with an additional 23 patients enrolled to date; initial data is expected in the first half of 2025. 18 patients were enrolled; one patient remains on treatment. Luvelta plus bevacizumab demonstrated encouraging antitumor activity in 17 RECIST evaluable patients: At the RP2D, an Objective Response Rate of 56% was observed; no patients had a response at 3.5 mg/kg and 50% of patients had a response at 5.2 mg/kg. An ORR of 35% was observed in the overall population with a median duration of response of 9.3 months. In patients with greater than or equal to 25% FRalpha expression, an ORR of 44% was observed; in patients with less than25% FRalpha expression, an ORR of 29% was observed. No new safety signals were observed compared with either agent alone; consistent with previous reported luvelta safety results, the most common adverse event was neutropenia.

astroflyery1 Posted - 2 days ago

$STRO An ORR of 35% (6/17) was observed in the overall population with a median duration of response of 9.3 months. In patients with ≥25% FRα expression, an ORR of 44% (4/9) was observed; in patients with <25% FRα expression, an ORR of 29% (2/7) was observed.

astroflyery1 Posted - 2 days ago

$STRO “We are encouraged by these results achieved with luvelta in combination with bevacizumab, which may offer the opportunity to benefit ovarian cancer patients regardless of FRα expression,” said Jane Chung, Sutro’s President and Chief Operating Officer. “We have already seen promising antitumor activity with luvelta as a monotherapy treatment and we believe these combination data support our goal to deliver effective therapies to more patients living with cancer. We look forward to sharing initial results from our expansion phase in the first half of 2025.”

astroflyery1 Posted - 2 days ago

$STRO These early data in combination may offer a non-biomarker driven approach to treat patients with EOC. The expansion phase of the study is ongoing at the recommended phase 2 dose (RP2D) of luvelta (4.3 mg/kg) in combination with bevacizumab (15 mg/kg) with an additional 23 patients enrolled to date; initial data is expected in the first half of 2025.

astroflyery1 Posted - 2 days ago

$STRO Data released: - Luvelta in combination with bevacizumab demonstrated encouraging preliminary antitumor activity (35% response rate) across all explored dose ranges. - Expansion at RP2D is ongoing with an additional 23 patients enrolled to date; expansion data are expected in the first half of 2025 - No new safety signals were observed compared with either agent alone

Stock_Titan Posted - 2 days ago

$STRO Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 https://www.stocktitan.net/news/STRO/sutro-biopharma-announces-updated-data-from-phase-1b-study-of-ieta2fx43d8u.html

TrustButVerifi Posted - 3 days ago

$STRO Soon this will be discovered and 3-4X from here!

_www_larval_com_ Posted - 3 days ago

$STRO has soared 3% higher to 4% (~1Mv) a few minutes ago, 09/20 options, follow for more volatility.

betaino Posted - 4 days ago

$STRO https://www.linkedin.com/posts/sutro-biopharma-inc-_sutrobio-gyncsm-gynecologiccancer-activity-7240033388600901632-IsoS?utm_source=share&utm_medium=member_android

astroflyery1 Posted - 4 days ago

$STRO Data will be presented. Sep 14, 2024 3:00 am EDT European Society for Medical Oncology (ESMO) Congress 2024

Biotech2424 Posted - 5 days ago

$STRO When’s data coming here tomorrow??

astroflyery1 Posted - 5 days ago

$STRO Sutro Biopharma has become an established institution. It is holding a Research Forum to highlight it's next-generation ADCs on October 10, 2024 https://ir.sutrobio.com/news-events/news-releases/detail/198/sutro-biopharma-to-host-research-forum-highlighting-next-generation-adc-innovation-and-near-term-pipeline-on-october-10-2024

astroflyery1 Posted - 5 days ago

$STRO Sutro Biopharma is one of the most prestigious company in the ADC field. I'm very confident and at the same time delighted to be invested. I believe a buyout will be at least >$5bn as the underlying technology and pipeline are incredibly powerful.

betaino Posted - 5 days ago

$STRO https://www.linkedin.com/posts/sutro-biopharma-inc-_sutrobio-researchforum-webcast-activity-7239603751714504704-ZpbY?utm_source=share&utm_medium=member_android

astroflyery1 Posted - 1 week ago

$STRO STRO-004, one of Sutro Biopharma’s key assets, is a tissue factor-targeting ADC in development for solid tumors. It is still in the preclinical stage, with an Investigational New Drug (IND) application expected in 2025, making its potential market and revenue harder to fully quantify at this early stage. STRO-004 has potential applications in multiple solid tumors, including pancreatic, bladder, breast, colorectal, prostate, glioblastoma, gastric, and melanoma. Each of these cancers represents a large market, making STRO-004 a potentially versatile and high-value therapy across several indications.

astroflyery1 Posted - 1 week ago

$STRO Considering just these major indications, with conservative assumptions for market share and pricing, Sutro could generate $1-4 billion annually from its current pipeline if successful in bringing these therapies to market. The actual revenue will depend on factors such as clinical trial outcomes, pricing strategy, and market competition.

astroflyery1 Posted - 1 week ago

$STRO Endometrial Cancer - Patient population: Approximately 71,000 patients with FRα expression . - Revenue potential: Pricing strategies could lead to potential revenues in the hundreds of millions to $1 billion range, depending on market share and pricing.

astroflyery1 Posted - 1 week ago

$STRO Non-Small Cell Lung Cancer (NSCLC) - Patient population: Around 108,000 patients are expected to express FRα, making them eligible for Luvelta treatment . - Revenue potential: Pricing and market penetration could yield substantial revenues, potentially $1 billion+, depending on success in clinical trials and market uptake.

astroflyery1 Posted - 1 week ago

$STRO Luvelta (STRO-002) – (PROC) - Patient population: Luvelta is targeting platinum-resistant ovarian cancer (PROC) patients with folate receptor-alpha (FRα) expression. The presentation estimates an annual incidence of about 69,000 patients in the U.S., Europe, and Japan . - Revenue per patient: Assuming a price similar to other ADCs like ImmunoGen’s Elahere, which can range from $100,000 to $200,000 per patient annually, the revenue potential is substantial. - Estimated revenue: If Sutro captures just 10-20% of the total eligible population (6,900 to 13,800 patients), annual revenue from ovarian cancer alone could range between $690 million to $2.76 billion.